26250-84-0

Basic information

• Product Name: (S)-1-Boc-piperidine-2-carboxylic acid
• Synonyms: (S)-N-t-Butyloxycarbonyl-piperidine-2-carboxylic acid, Boc-L-pipecolic acid;N-Boc-L-pipecolinic acid, 98+%;(S)-1-Boc-piperidine-2-carboxylic acid, N-Boc-L-pipecolinic acid, (S)-(-)-1-(tert-Butoxycarbonyl)-2-piperidinecarboxylic acid;N-ALPHA-T-BOC-L-PIPECOLIC ACID;N-ALPHA-T-BUTOXYCARBONYL-L-PIPECOLIC ACID;N-ALPHA-T-BUTOXYCARBONYL-L-HOMOPROLINE;N-BOC-(S)-PIPECOLINIC ACID;N-BOC-L-PICOLINIC ACID
• CAS NO: 26250-84-0
• Molecular Formula: C₁₁H₁₉NO₄
• Molecular Weight: 229.27
• Product Categories: chiral;Chiral Reagent;Amino Acids;Amino Acid Derivatives;Unusual amino acids;Hyterocycles;Chiral Reagents;Miscellaneous Reagents
• Mol File: 26250-84-0.mol

Chemical Properties

• Melting Point: 122-126 °C(lit.)
• Boiling Point: 353.2 °C at 760 mmHg
• Flash Point: 167.4 °C
• Appearance: White to off-white/Powder
• Density: 1.164 g/cm³
• Vapor Pressure: 6.15E-06mmHg at 25°C
• Refractive Index: 1.496
• Storage Temp.: Store at RT.
• Solubility: Chloroform, Methanol
• PKA: 4.03±0.20(Predicted)
• Water Solubility: Insoluble in water.
• BRN: 3652038
• CAS DataBase Reference: (S)-1-Boc-piperidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-Boc-piperidine-2-carboxylic acid(26250-84-0)
• EPA Substance Registry System: (S)-1-Boc-piperidine-2-carboxylic acid(26250-84-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36-36/37/39-22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 26250-84-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-Boc-piperidine-2-carboxylic acid is used as a modulating agent for ion channel activity. Its ability to interact with ion channels makes it a promising candidate for the development of new drugs targeting various neurological and cardiovascular conditions.
Used in Proteomics Research:
In the field of proteomics, (S)-1-Boc-piperidine-2-carboxylic acid serves as a useful boc-protected pipecolic acid. It aids in the study of protein expression and function, particularly in the context of ion channel modulation, which is crucial for understanding the underlying mechanisms of various diseases and developing targeted therapies.

InChI:InChI=1/C11H19NO4/c1-11(2,3)16-10(15)12-7-5-4-6-8(12)9(13)14/h8H,4-7H2,1-3H3,(H,13,14)/t8-/m0/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 3105-95-1 pipecolinic acid 
• 4043-87-2 pipecolic Acid 
• 150521-32-7 (S)-1-N-Boc-piperidine-2-al 
• 7681-38-1 sodium hydrogen sulfate 
• 13406-98-9 dihydropyridinemonocarboxylic acid 
• 596129-25-8 (+/-)-N-trifluoroacetyl pipecolic acid 
• 596129-26-9 (S)-1-(2,2,2-Trifluoro-acetyl)-piperidine-2-carboxylic acid (S)-3,4,4-trimethyl-2-oxo-tetrahydro-furan-3-yl ester 
• 417726-34-2 (S)-2-((S)-1,2-Dihydroxy-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 417726-36-4 (S)-1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridine-2-carboxylic acid 
• 259133-67-0 2-carboxy-N-Boc-1,4,5,6-tetrahydropyridine 
• 220926-89-6 (S)-2-[(E)-styryl]piperidine-1-carboxylic acid tert-butyl ester 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 116611-45-1 (2R)-2-t-butoxycarbonylamino-3-phenylsulfonyl-1-(2-tetrahydropyranyloxy)propane 

Downstream Products

• 500213-45-6 (S)-2-((S)-1-Methoxycarbonyl-2-phenyl-ethylcarbamoyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 187851-81-6 (S)-Piperidine-1,2-dicarboxylic acid 2-((R)-1-benzyloxycarbonyl-ethyl) ester 1-tert-butyl ester 
• 906537-42-6 (S)-tert-butyl 2-((R)-1-((2R,4R)-2-(3-azidopropyl)-4-(naphthalen-2-ylmethoxy)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-ylcarbamoyl)piperidine-1-carboxylate 
• 906537-68-6 (S)-tert-butyl 3-((R)-1-((2R,4S)-2-(3-azidopropyl)-4-(naphthalen-2-ylmethoxy)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-ylcarbamoyl)piperidine-1-carboxylate 
• 906536-47-8 (S)-tert-butyl 2-((R)-1-((2S,4R)-2-(3-azidopropyl)-4-(naphthalen-2-ylmethoxy)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-ylcarbamoyl)piperidine-1-carboxylate 
• 906537-58-4 (S)-tert-butyl 3-((R)-1-((2S,4S)-2-(3-azidopropyl)-4-(naphthalen-2-ylmethoxy)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-ylcarbamoyl)piperidine-1-carboxylate 
• 906536-10-5 (S)-tert-butyl 3-((R)-1-((2R,4R)-2-(2-(benzyloxycarbonylamino)ethylcarbamoyl)-4-(naphthalen-2-ylmethoxy)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-ylcarbamoyl)piperidine-1-carboxylate 
• 910568-08-0 (S)-2-[(R)-2-[(S)-2-(3-Benzyloxycarbonylamino-propyl)-4-((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-3-oxo-piperazin-1-yl]-1-(4-fluoro-benzyl)-2-oxo-ethylcarbamoyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 502633-94-5 N-Boc-L-pipecolic acid ethyl ester 
• 500213-61-6 (S)-2-({(S)-1-[(S)-2-[(S)-2-({(S)-1-[(S)-2-tert-Butoxycarbonylamino-3-(1H-indol-3-yl)-propionyl]-piperidine-2-carbonyl}-amino)-3-phenyl-propionylamino]-3-(1H-indol-3-yl)-propionyl]-piperidine-2-carbonyl}-amino)-3-phenyl-propionic acid methyl ester 
• 500213-59-2 (S)-2-({(S)-1-[(S)-2-((S)-2-{[(S)-1-((S)-2-tert-Butoxycarbonylamino-3-phenyl-propionyl)-piperidine-2-carbonyl]-amino}-3-phenyl-propionylamino)-3-phenyl-propionyl]-piperidine-2-carbonyl}-amino)-3-phenyl-propionic acid methyl ester 
• 500213-46-7 (S)-2-{[(S)-1-((S)-2-tert-Butoxycarbonylamino-3-phenyl-propionyl)-piperidine-2-carbonyl]-amino}-3-phenyl-propionic acid methyl ester 

Relevant articles and documents

Straightforward entry to the pipecolic acid nucleus. Enantioselective synthesis of baikiain

New enantioselective syntheses of N-protected baikiain and pipecolic acid have been developed. The starting material is 2,3-epoxy-5-hexen-1-ol (4) readily available in high ee by Sharpless epoxidation. The regio- and stereoselective epoxide ring-opening by allylamine afforded a doubly unsaturated amine that was converted into a carbamate (Boc) and submitted to ring-closing metathesis. The resulting cyclic amino diol 6 is a key intermediate that was converted into N-Boc-baikiain and several pipecolic acid derivatives.

Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants

A novel class of HIV-1 protease inhibitors with flexible piperidine as the P2 ligand was designed with the aim of improving extensive interactions with the active subsites. Many inhibitors exhibited good to excellent inhibitory effect on enzymatic activity and viral infectivity. In particular, inhibitor 3a with (R)-piperidine-3-carboxamide as the P2 ligand and 4-methoxybenzenesulfonamide as the P2’ ligand showed an enzyme Ki value of 29 pM and antiviral IC50 value of 0.13 nM, more than six-fold enhancement of activity compared to DRV. Furthermore, there was no significant change in potency against DRV-resistant mutations and HIV-1NL4?3 variant for 3a. Besides, inhibitor 3a exhibited potent antiviral activity against subtype C variants with low nanomole EC50 values. In addition, the molecular modeling revealed important hydrogen bonds and other favorable van der Waals interactions with the backbone atoms of the protease and provided insight for designing and optimizing more potent HIV-1 protease inhibitors.

Targeted Covalent Inhibition of Plasmodium FK506 Binding Protein 35

FK506-binding protein 35, FKBP35, has been implicated as an essential malarial enzyme. Rapamycin and FK506 exhibit antiplasmodium activity in cultured parasites. However, due to the highly conserved nature of the binding pockets of FKBPs and the immunosuppressive properties of these drugs, there is a need for compounds that selectively inhibit FKBP35 and lack the undesired side effects. In contrast to human FKBPs, FKBP35 contains a cysteine, C106, adjacent to the rapamycin binding pocket, providing an opportunity to develop targeted covalent inhibitors of Plasmodium FKBP35. Here, we synthesize inhibitors of FKBP35, show that they directly bind FKBP35 in a model cellular setting, selectively covalently modify C106, and exhibit antiplasmodium activity in blood-stage cultured parasites.

MORPHINAN DERIVATIVE

A compound represented by the following general formula (I), wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms and the alkylene moiety has 1 to 5 carbon atoms, or the like, R2 represents a 4- to 7-membered saturated heterocycle containing one or two heteroatoms which may be the same or different and are selected from N, O, and S, and two or more carbon atoms as ring-constituting atoms, the heterocycle may be substituted with a substituent such as an oxo group, R2 binds to Y via a carbon atom as a ring-constituting atom of R2, R3, R4, and R5, which are the same or different, represent hydrogen; hydroxy; or the like, R6a and R6b, which are the same or different, represent hydrogen or the like, R7 and R8, which are the same or different, represent hydrogen or the like, R9 and R10, which are the same or different, represent hydrogen or the like, X represents O or CH2, and Y represents C(= O) or the like), a tautomer of the compound, a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic, an antidepressant, or the like.

Lipase-catalyzed asymmetric synthesis of naphtho[2,3-c]furan-1(3H)-one derivatives by a one-pot dynamic kinetic resolution/intramolecular Diels–Alder reaction: Total synthesis of (?)-himbacine

One-pot sequential reactions using the acyl moieties installed by enzymatic dynamic kinetic resolution of alcohols have been little investigated. In this work, the acryloyl moiety installed via the lipase/oxovanadium combo-catalyzed dynamic kinetic resolution of a racemic dienol [4-(cyclohex-1-en-1-yl)but-3-en-2-ol or 1-(cyclohex-1-en-1-yl)but-2-en-1-ol] with a (Z)-3-(phenylsulfonyl)acrylate underwent an intramolecular Diels–Alder reaction in a one-pot procedure to produce an optically active naphtho[2,3-c]furan-1(3H)-one derivative (98% ee). This method was successfully applied to the asymmetric total synthesis of (?)-himbacine.

Design and Discovery of Novel Chiral Antifungal Amides with 2-(2-Oxazolinyl)aniline as a Promising Pharmacophore

Inspired by established succinate dehydrogenase inhibitors (SDHIs), our continuing efforts toward the discovery of chiral antifungal amides turned to the optimization of their polar regions with 2-(2-oxazolinyl)aniline as a known pharmacophore. Scaffold hopping and bioactivity-guided convergent synthesis enabled the identification of promising antifungal categories. Fine tuning of the substituents and chirality furnished seven amides (1s, 1t, 2d, 2h, 2j, 3k, and 2l) as antifungal candidates, with EC50 values lower than 5 mg/L. The first investigation of chiral amides of acyclic acids as SDHIs was conducted, and compound 2d was selected as a promising candidate against Botrytis cinerea, with a preventative efficacy of up to 93.9% at 50 mg/L, which is better than that of boscalid. The different binding models between compounds with different configurations were simulated for compound 2d and its diastereoisomers. The benefits of synthetic accessibility and cost-effectiveness highlight the practical potential for compound 2d as a good alternative to known SDHI fungicides.

Stereoselective synthesis of (?)-3-PPP through palladium-catalysed unactivated C(sp3)–H arylation at the C-3 position of L-pipecolinic acid

An efficient route for the preparation of (?)-3-PPP(preclamol) using the highly stereoselective palladium-catalysed C(sp3)-H arylation and radical decarboxylation reaction as the key steps is described. The chiral center at the C-3 position of

COSMETIC USES AND METHODS FOR INDOLINE GRANZYME B INHIBITOR COMPOSITIONS

Cosmetic uses and methods for indoline granzyme B inhibitor compounds in compositions with a cosmetically acceptable carrier. Uses and methods for treating, reducing or inhibiting the appearance of ageing in the skin are provided. Also provided are compositions and formulation for cosmetic uses and methods of maintaining a youthful appearance, reducing an appearance of ageing, inhibiting an appearance of ageing, reducing a rate of an appearance of ageing, reducing a skin inelasticity, reducing a rate of increasing skin inelasticity, maintaining a skin elasticity, and increasing the density of hair follicles of a skin of a subjecl. The uses and methods comprise applying/administering an indoline granzyme B inhibitor to a skin, or a portion of a skin of the subject.

L-Pipecolinic acid derived Lewis base organocatalyst for asymmetric reduction of N-aryl imines by trichlorosilane: Effects of the side amide group on catalytic performances

A series of N-formamides derived from pipecolinic acid have been synthesized and tested as Lewis base catalysts for the enantioselective reduction of N-aryl imines by trichlorosilane. Through the investigation of the structure-efficacy relationship between the side amide group and catalytic performance, several highly effective catalysts were discovered. In particular, arylamido-type catalyst 5i and non-arylamido-type catalyst 6c exhibited high reactivity and enantioselectivity, furnishing the reduction of a wide variety of N-aryl imines with high isolated yields (up to 98%) and ee values (up to 96%) under mild conditions. Moreover, these two catalysts complement each other in terms of their tolerances to nonaromatic ketimines and non-methyl ketimines. The Royal Society of Chemistry 2013.

Discovery of 23 Natural Tubulysins from Angiococcus disciformis An d48 and Cystobacter SBCb004

The tubulysins are a family of complex peptides with promising cytotoxic activity against multi-drug-resistant tumors. To date, ten tubulysins have been described from the myxobacterial strains Angiococcus disciformis An d48 and Archangium gephyra Ar 315. We report here a third producing strain, Cystobacter sp. SBCb004. Comparison of the tubulysin biosynthetic gene clusters in SBCb004 and An d48 reveals a conserved architecture, allowing the assignment of cluster boundaries. A SBCb004 strain containing a mutant in the putative cyclodeaminase gene tubZ accumulates pretubulysin A, the proposed first enzyme-free intermediate in the pathway, whose structure we confirm by NMR. We further show, using a combination of feeding studies and structure elucidation by NMR and high-resolution tandem mass spectrometry, that SBCb004 and An d48 together biosynthesize 22 additional tubulysin derivatives. These data reveal the inherently diversity-oriented nature of the tubulysin biosynthetic pathway.